Collaboration will further assess novel investigational cancer treatments combined with standard chemotherapy
PIVOTAL and APRO have announced today a close collaboration in 3 different oncology clinical trials to test...
Pivotal has been selected as one of the few firms that attracted recognition from the Pharma IQ network as a “RISING STAR"
We´re delighted to bring to...
New collaboration aims to further accelerate the delivery of novel treatments for multiple difficult-to-treat cancers in Europe
Sarah Cannon Development Innovations announced today a new strategic collaboration with Pivotal...
The annual conference was held in San Francisco (California)
Pivotal, represented by members of our Senior Management, has participated in the 36th Annual JP Morgan HealthCare Conference held in...
ESMO took place in Madrid from the 08th until the 12th of September
On Tuesday, September 12th, the European Society for Medical Oncology Congress (ESMO) ended in Madrid as...
Pivotal and ESMO working on different levels to improve prevention, diagnosis, treatment, and palliative care of cancer patients through clinical research
Pivotal, the Madrid-based, European-wide Clinical Research Organization (CRO),...
Important online media coverage
On Sunday, June 25th, the 22nd European Hematology Association Congress (EHA) came to a close. The conference was held at the IFEMA Trade Fair Institution...
The EHA congress will be held for the first time in Madrid
Pivotal, the Madrid-based European-wide Clinical Research Organisation (CRO), is participating with a booth at the forthcoming <a...
All fields are required